Severe psoriasis treated with a new macrolide: Everolimus

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 372-374

  Frigerio, E ^a   Colombo, M D ^b   Franchi, C ^a   Altomare, A ^a   Garutti, C ^a   Altomare, G F ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Dipartimento di Dermatologia   (Italy)

Author keywords

Ciclosporin; Everolimus; Psoriasis

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; MACROLIDE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CASE REPORT; DESQUAMATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LYMPHOCYTE COUNT; PATIENT MONITORING; PRIORITY JOURNAL; PSORIASIS VULGARIS; SINGLE DRUG DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

CYCLOSPORINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PSORIASIS; SIROLIMUS; TREATMENT OUTCOME;

EID: 33846189774     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07602.x     Document Type: Article

References (11)

1. Robert C, Kupper TS. Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 1999; 341:1817-28.
2. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002; 11:1845-57.
3. Schuurman HJ, Cottens S, Fuchs S et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64:32-5.
4. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997; 64:36-42.
5. Reitamo S, Spuls P, Sassolas B et al. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145:438-45.
6. Ormerod AD, Shah SA, Copeland P et al. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005; 152:758-64.
7. Li VW, Li WW. Cyclosporine and angiogenesis in psoriasis. J Am Acad Dermatol 1996; 35:1019-21.
8. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995; 159:113-60.
9. Kovarik JM, Kahan BD, Kaplan B et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001; 69:48-56.
10. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety data and efficacy results of two randomized studies. Am J Transplant 2004; 4:626-35.
11. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 2003; 349:848-58.